Sopharma AD-Sofia (XBUL:SFA) 3-Year EBITDA Growth Rate : 21.00% (As of Jun. 2024)

View and export this data going back to 2000. Start your Free Trial

What is Sopharma AD-Sofia 3-Year EBITDA Growth Rate?

Sopharma AD-Sofia's EBITDA per Share for the three months ended in Jun. 2024 was лв0.19.

During the past 12 months, Sopharma AD-Sofia's average EBITDA Per Share Growth Rate was -20.50% per year. During the past 3 years, the average EBITDA Per Share Growth Rate was 21.00% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 13.20% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was 10.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Sopharma AD-Sofia was 28.70% per year. The lowest was -4.70% per year. And the median was 9.30% per year.

Competitive Comparison of Sopharma AD-Sofia's 3-Year EBITDA Growth Rate

For the Medical Distribution subindustry, Sopharma AD-Sofia's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sopharma AD-Sofia's 3-Year EBITDA Growth Rate Distribution in the Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Sopharma AD-Sofia's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Sopharma AD-Sofia's 3-Year EBITDA Growth Rate falls into.

Sopharma AD-Sofia 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Sopharma AD-Sofia (XBUL:SFA) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Sopharma AD-Sofia 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Sopharma AD-Sofia's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Sopharma AD-Sofia Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Sopharma AD-Sofia (XBUL:SFA) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

SPH:Poland

Address

5 Lachezar Stanchev Street, Sopharma Business Towers, Building A, Floor 11, Sofia, BGR, 1756

Website

https://www.sopharmagroup.com

Sopharma AD-Sofia is a company engaged in the production of pharmaceutical products. Its principal activities include the production and trade of medicinal substances and finished drug forms; and research and development as well as engineering and implementation activities in the field of medicinal products. It is also focused on the distribution of pharmaceuticals like medical supplies, sanitary materials, vitamins, food supplements, and cosmetics. The company's segments are the Production of pharmaceutical products; Distribution of pharmaceutical products; and Others. It generates the majority of its revenue from the Distribution of pharmaceutical products.

Sopharma AD-Sofia Headlines

No Headlines